Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
LOS ANGELES (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.
from Reuters: Health News https://reut.rs/2Jn12kQ
http://bit.ly/2zwRqiM
April 24, 2018
|
Labels:
health,
Reuters: Health News
|
This entry was posted on April 24, 2018
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.